Lantern Pharma (LTRN)

Executive Summary

Lantern Pharma is a clinical-stage oncology company that leverages its proprietary AI and machine learning platform, RADAR, to accelerate drug discovery and development while reducing costs. The platform integrates genomic data and disease models to identify patient populations most likely to respond to therapies, thereby improving trial efficiency and success rates. The company's pipeline includes multiple programs targeting solid tumors and hematological malignancies, with a focus on precision medicine approaches. Key assets include LP-300 (Phase 2 for non-small cell lung adenocarcinoma), LP-184 (Phase 1/2 for advanced solid tumors and GBM), and LP-284 (Phase 1 for relapsed/refractory lymphomas). Lantern's strategy emphasizes in-licensing and repurposing drugs, combined with AI-driven biomarker discovery to de-risk development. The company went public via a SPAC merger in 2021 and maintains a lean operational model, with a valuation around $23 million as of early 2026. Despite limited near-term revenue, Lantern's differentiated platform and multiple clinical readouts in 2026-2027 position it as a potential value opportunity in precision oncology.

Upcoming Catalysts (preview)

• Q3 2026LP-300 Phase 2 Top-Line Data in NSCLC65% success
• Q2 2026LP-184 Phase 1/2 Combination Data Update (e.g., ASCO 2026)50% success
• H2 2026Potential Strategic Partnership for LP-184 or AI Platform (RADAR)30% success